Leverage Shares 2X Long FIX Daily ETF (BATS:FIXX – Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 2,770 shares, a decrease of 45.0% from the October 15th total of 5,039 shares. Approximately 5.0% of the company’s shares are sold short. Based on an average trading volume of 15,335 shares, the short-interest ratio is presently 0.2 days.
Leverage Shares 2X Long FIX Daily ETF Price Performance
FIXX opened at $4.59 on Tuesday. Leverage Shares 2X Long FIX Daily ETF has a one year low of $3.83 and a one year high of $15.92. The firm’s 50 day simple moving average is $10.13.
Insider Activity
In related news, CFO Lee Kalowski sold 3,972 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $65,776.32. Following the sale, the chief financial officer directly owned 138,471 shares of the company’s stock, valued at $2,293,079.76. This trade represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia M. Violette sold 2,798 shares of the business’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the transaction, the insider owned 127,771 shares in the company, valued at approximately $2,115,887.76. This represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 22,054 shares of company stock valued at $320,397.
About Leverage Shares 2X Long FIX Daily ETF
Homology Medicines, Inc. was a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare diseases. The company sought to use its proprietary human-derived adeno-associated virus vectors, known as AAVHSCs, to deliver gene therapies in vivo and address the underlying causes of inherited disorders. Its development programs included HMI-103, an investigational gene therapy for phenylketonuria, as well as earlier programs targeting other rare diseases. Homology also explored the use of its platform for gene editing and other genetic medicine applications.
Featured Stories
- Five stocks we like better than Leverage Shares 2X Long FIX Daily ETF
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Leverage Shares 2X Long FIX Daily ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leverage Shares 2X Long FIX Daily ETF and related companies with MarketBeat.com's FREE daily email newsletter.
